Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
The efficacy of osimertinib is severely limited by the emergence of EGFR C797S, which is detected in either the cis or trans position with T790M when osimertinib is used as a second-line treatment, and which is largely identified in combination with an EGFR 19 deletion. The EGFR T790M-cis-G796S muta...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2022-04-01
|
| Serier: | Frontiers in Oncology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fonc.2022.875313/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|